Novo Nordisk A/S (NYSE:NVO) is one of the 12 Best European Dividend Stocks to Buy Now. Berenberg lowered NVO’s price target to DKK 400 but maintained a Buy rating. The company announced a price cut to compete with Eli Lilly in the obesity-drug market, offering Oze‌mpic at $349 per month. In Q3 2025, NVO reported revenue of DKK 154.94 billion, up 16.1% year-on-year, with operating profit rising 25%. Novo Nordisk is a global healthcare company focusing on diabetes treatments. Consider investing in NVO, but explore other AI stocks for greater potential. No disclosure.

Read more at Yahoo Finance: Berenberg Lowers Novo Nordisk (NVO) Price Target to DKK 400, Maintains Buy Rating